By Maurie Markman, MD
Cancer Treatment Centers of America
Drexel University College of Medicine
Philadelphia, Pennsylvania
Today, there can be no legitimate debate within the oncology realm regarding the importance of end-of-life discussions with appropriate patients and their families. Most oncologists are well aware of examples of patients who received toxic therapy beyond the point where there was any realistic possibility for clinical benefit to have occurred and, conversely, where